Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337129 | 0.93 | MEN1 (0.63) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027731 | 0.92 | MEN1 (0.71) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027994 | 0.89 | MEN1 (0.63) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL10643552 | 0.88 | MEN1 (0.48) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL2891553 | 0.88 | MEN1 (0.66) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL10644355 | 0.88 | MEN1 (0.51) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL2892060 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3336560 | 0.86 | MEN1 (0.68) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13028036 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13028034 | 0.86 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4864 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-4646432-A1 | ANTI-IL-18BP ANTIBODIES | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4646433-A1 | ANTI-IL-18BP ANTIBODIES | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| EP-4590341-A1 | POLYMERS WITH DUAL THERAPEUTIC AGENTS | Sony Group Corporation (JP) | 2025-07-30 | — | — | EP | claimed |
| US-20250215505-A1 | MGMT EPIGENETIC DEEP-SEQUENCING ASSAY | MDXHEALTH SA (BE) | 2025-07-03 | — | — | US | claimed |
| CN-120152742-A | Polymer with dual therapeutic agents | 索尼集团公司 | 2025-06-13 | — | — | CN | claimed |
| US-20250188170-A1 | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES | ATYR PHARMA, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250032413-A1 | ULTRASONICALLY-ENHANCED CONTINUOUS AND LARGE-SCALE PRODUCTION METHOD FOR NANO-FORMULATIONS | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-01-30 | — | — | US | claimed |
| US-20250009786-A1 | AUTOMATED SYNTHESIS OF POLYMERIC DUAL DRUGS | Sony Group Corporation (JP) | 2025-01-09 | — | — | US | claimed |
| CN-1679952-A | Anticarcinogenic medicine composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1679946-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1660436-A | Anticancer combination of medication | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-08-31 | — | — | CN | claimed |
| WO-2005068465-A1 | 2-AMINO-O4-SUBSTITUTED PTERIDINES AND THEIR USE AS INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-28 | — | — | WO | claimed |
| CN-1628850-A | Anti solid tumor medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | claimed |
| CN-1628849-A | Anticancer medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | claimed |
| CN-1628851-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | claimed |
| CN-1616098-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-05-18 | — | — | CN | claimed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | claimed |
| US-5260291-A | Tetrazine derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-11-09 | — | — | US | claimed |